核素示踪靶向肿瘤新生血管分子探针的研究进展

王荣福; 王荣福

doi:10.3760/cma.j.issn.1673-4114.2015.01.011

[1]

Liu H, Bao D, Xia X, et al. An unconventional role of BMP-Smad1 signaling in DNA damage response:a mechanism for tumor suppression[J]. J Cell Biochem, 2014, 115(3):450-456. doi: 10.1002/jcb.24698

[2]

徐小雯, 傅传刚.抗血管生成药物改善肿瘤血供及含氧量的机制探讨和应用展望[J].中华胃肠外科杂志, 2014, 17(11):1148-1150. doi: 10.3760/cma.j.issn.1671-0274.2014.11.23

[3]

Wong MM, Guo C, Zhang J. Nuclear receptor corepressor complexes in cancer:mechanism, function and regulation[J]. Am J Clin Exp Urol, 2014, 2(3):169-187.

[4]

Rubin MA. Insights into the mechanism of organ-specific cancer metastasis[J]. Cancer Discov, 2014, 4(11):1262-1264. doi: 10.1158/2159-8290.CD-14-1075

[5]

Lee J, Lee TS, Ryu J, et al. RGD peptide-conjugated multimodal NaGdF4:Yb³⁺/Er³⁺ nanophosphors for upconversion luminescence, Mr, and PET imaging of tumor angiogenesis[J]. J Nucl Med, 2013, 54(1):96-103.

[6]

Kang L, Wang RF, Yan P, et al. Noninvasive visualization of RNA delivery with ^99mTc-radiolabeled small-interference RNA in tumor xenografts[J]. J Nucl Med, 2010, 51(6):978-986.

[7]

王荣福.分子核医学应用研究进展[J].中国临床医学影像杂志, 2008, 19(8):585-590. doi: 10.3969/j.issn.1008-1062.2008.08.015

[8]

王荣福.核医学[M]. 3版.北京: 北京大学医学出版社, 2013.

[9]

Liu M, Wang RF, Zhang CL, et al. Noninvasive imaging of human telomerase reverse transcriptase(hTERT)messenger RNA with ^99mTc-radiolabeled antisense probes in malignant tumors[J]. J Nucl Med, 2007, 48(12):2028-2036. doi: 10.2967/jnumed.107.042622

[10]

王荣福.肿瘤分子功能显像诊断与靶向治疗[J].肿瘤学杂志, 2010, 16(6):421-422.

[11]

Roessler S, Budhu A, Wang XW. Deciphering cancer heterogeneity:the biological space[J]. Front cell dev biol, 2014, 2:12.

[12]

王荣福.核素示踪技术在疾病诊治中的应用[J].肿瘤学杂志, 2013, 19(12):911-913.

[13]

Yu Y, He J. Molecular classification of non-small-cell lung cancer:diagnosis, individualized treatment, and prognosis[J]. Front Med, 2013, 7(2):157-171.

[14]

王荣福. PET/CT-分子影像学新技术应用[M].北京: 北京大学医学出版社, 2011.

[15]

王荣福. PET/CT新技术应用[J]. CT理论与应用研究, 2009, 18(4):9-14.

[16]

Price P, Jones T. Can positron emission tomography(PET)be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group[J]. Eur J Cancer, 1995, 31A(12):1924-1927.

[17]

王荣福. PET/CT肿瘤诊断学[M].北京: 北京大学医学出版社, 2008.

[18]

王金娥, 陈刚. ¹⁸F-FDG PET/CT对淋巴瘤化疗疗效的评估[J].肿瘤学, 2014, 20(11):898-904.

[19]

王荣福.核医学分子功能成像和靶向治疗在淋巴瘤中临床应用进展[J].肿瘤学杂志, 2009, 15(9):861-865.

[20]

Sulakhe D, Balasubramanian S, Xie B, et al. High-throughput translational medicine:challenges and solution[J]. Adv Exp Med Biol, 2014, 799(1):39-67.

[21]

Lu X, Wang RF. A concise review of current radiopharmaceuticals in tumor angiogenesis imaging[J]. Curr Pharm Des, 2012, 18(8):1032-1040. doi: 10.2174/138161212799315812

[22]

Brown CK, Modzelewski RA, Johnson CS, et al. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli Peptide Display Library[J]. Ann Surg Oncol, 2000, 7(10):743-749. doi: 10.1007/s10434-000-0743-0

[23]

Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine[J]. Cancer Res, 2005, 65(2):533-539.

[24]

刘红洁, 王荣福, 张春丽, 等. ¹³¹Ⅰ标记RGD环肽在荷瘤小鼠体内分布与显像研究[J].中国医学影像技术, 2008, 24(1):131-133. doi: 10.3321/j.issn:1003-3289.2008.01.038

[25]

Yu MM, Wang RF, Yan P, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma[J]. J Labelled Comp Radiopharm, 2008, 51(11/12):374-378.

[26]

王荣福, 于明明, 闫平, 等.碘标记肿瘤血管靶向多肽研究[J].同位素杂志, 2009, 22(2):96-100.

[27]

Lu X, Yan P, Wang RF, et al. The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging[J/OL]. J Radioanal Nucl Chemistry, 2011, 290(3): 623-630[2014-12-20]. http://link.springer.com/article/10.1007%2FS10967-011-1342-1.

[28]

于明明, 王荣福, 张春丽, 等. ¹³¹I标记精氨酸-精氨酸-亮氨酸多肽在荷瘤小鼠体内的分布与显像[J].中国医学影像技术, 2009, 25(1):10-14. doi: 10.3321/j.issn:1003-3289.2009.01.004

[29]

Yu M, Zhou H, Liu X, et al. Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma[J]. Ann Nucl Med, 2010, 24(1):13-19.

[30]

Lu X, Yan P, Wang RF, et al. Use of radioiodinated peptide Arg-Arg-Leu targeted to neovasculari- zation as well as tumor cells in molecular tumor imaging[J]. Chin J Cancer Res, 2012, 24(1):52-59. doi: 10.1007/s11670-012-0052-8

[31]

Zhao Q, Yan P, Yin L, et al. Validation study of ¹³¹I-RRL:assessment of biodistribution, SPECT imaging and radiation dosimetry in mice[J]. Mol Med Rep, 2013, 7(4):1355-1360. doi: 10.3892/mmr.2013.1338

[32]

Zhao Q, Yan P, Wang RF, et al. A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study[J/OL]. PLoS One, 2013, 8(4): e61043[2014-12-20].http://journals. plos. org/plosone/article?id=10. 1371/journal. pone. 0061043.

[33]

崔永刚, 张春丽, 王荣福, 等. ¹³¹I标记cRGD环肽对荷黑色素瘤小鼠靶向治疗作用[J].中华核医学杂志, 2009, 29(2):92-95. doi: 10.3760/cma.j.issn.0253-9780.2009.02.006

[34]

张春丽, 王荣福, 张丽, 等.靶向整合素α_vβ₃受体的二硫键成环的RGD肽的设计、¹³¹I标记及在荷瘤鼠中的生物分布与显像[J].肿瘤学杂志, 2010, 16(4):276-280. doi: 10.3760/cma.j.issn.1673-422X.2010.04.012

[35]

刘红洁, 王荣福, 张春丽. RGD肽在肿瘤显像和治疗中的应用研究进展[J].肿瘤学杂志, 2008, 14(8):620-622.

[36]

张丽, 张春丽, 王荣福, 等. RGD多肽类药物设计、活性测定及⁹⁹Tc^m-cRGD二聚体的制备[J].核化学与放射化学, 2011, 33(2):106-113.

[37]

张春丽, 王荣福, 张丽, 等.靶向整合素α_vβ₃受体的新型RGD肽二聚体的~¹³¹I标记与生物活性的初步评价[J].北京大学学报:医学版, 2011, 43(2):295-300.

[38]

李玲, 张春丽, 王荣福.整合素α_vβ₃非肽类小分子拮抗剂的设计及其在肿瘤显像中的研究进展[J].同位素, 2010, 23(4):247-252.

[39]

Shastry BS. Phamacogenetics and the concept of individualized medicine[J]. Phamacogenomics J, 2006, 6(1):16-21.

[40]

Mcdermott U, Pusapati R V, Christensen J G, et al. Acquired resistance of non-small cell lung cancer cells to Met kinase inhibition is mediated by a Switch to epidermal growth factor receptor dependency[J]. Cancer Res, 2010, 70(4):1625-1634.

[41]

钟南山.中国临床医生转化医学实践之路[J].中国实用内科杂志, 2012, 32(7):481-483.

[42]

崔志文, 夏烨, 孙小娟, 等.国内外转化医学发展历程与展望[J].生命科学, 2012, 24(4):316-320.

[43]

付小兵.中国的再生医学研究:需求与转化应用[J].解放军医学杂志, 2012, 37(3):169-171.

[44]

王荣福.核医学分子靶向诊断与治疗[J].肿瘤学杂志, 2014, 20(11):871-874. doi: 10.11735/j.issn.1671-170X.2014.11.B001

[45]

Yao N, Chen XQ, Wang RF. Application progress of nano-material in molecule functional imaging with radionuclide tracing technique and targeted treatment[J]. J Mol Biol Techniques, 2014, 1(1):1-5.

[46]

Zhu ZH, Miao WB, Li QW, et al. ^99mTc-3PRGD2 for integrin receptor imaging of lung cancer:a multicenter study[J]. J Nucl Med, 2012, 53(5):716-722.

[47]

Shi J, Fan D, Dong C, et al. Anti-tumor effect of integrin targeted¹⁷⁷Lu-3PRGD2 and combined therapy with Endostar[J]. Theranostics, 2014, 4(3):256-266. doi: 10.7150/thno.7781